The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.
Lang
Veronika R
VR
Department of Internal Medicine 3, University of Erlangen–Nuremberg, Erlangen, Germany.
Mielenz
Dirk
D
Neubert
Kirsten
K
Böhm
Christina
C
Schett
Georg
G
Jäck
Hans-Martin
HM
Voll
Reinhard E
RE
Meister
Silke
S